Cerebrospinal fluid (CSF) biomarkers of Alzheimer disease (AD) are currently being considered for inclusion in revised diagnostic criteria for research and/or clinical purposes to increase the certainty of antemortem diagnosis.
Comparison of analytical platforms for cerebrospinal fluid measures of ?-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.